ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.
 PMID: 23364785       2013       Journal of medical virology
Abstract: In the plasma virus from treatment experienced patients with Y181C, A98G, V108I, and/or K101E mutations in the pol gene, higher IC(50) values were found in line with reduced susceptibility data for ETR.


  Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
 PMID: 23443042       2013       Journal of the International AIDS Society
Table: V108I


  Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.
 PMID: 23469241       2013       PloS one
Table: V108I


  Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
 PMID: 23629015       2013       The Journal of antimicrobial chemotherapy
Abstract: For rilpivirine, V108I and Y188I were more frequent in B than non-B subtypes, whereas V90I was more prevalent in non-B subtypes.


  Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India.
 PMID: 23735817       2013       Journal of the International AIDS Society
Method: Non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations that we assessed included K103N, Y181C, Y181I, G190A, G190S, V108I, Y188L, V106M, K103NS, K101E and G190E.


  HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana.
 PMID: 23977189       2013       PloS one
Result: In the case of NVP and EFV resistance, K103N, V106A, V108I, Y181C/L, G190A, P225H, and M230L mutations were detected in more than half of patients after 6.0 months of ART (blue bars in.
Result: In this case, both 3TC-resistance (M184V) and EFV-resistance (V108I and G190S) mutations were detected (Table 5).
Table: V108I


  Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.
 PMID: 24009694       2013       PloS one
Table: V108I


  Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina.
 PMID: 24093951       2013       Journal of the International AIDS Society
Discussion: At the mutation level, K103N represents around the 50% of NNRTI primary resistance in the last two periods while the remaining 50% was dominated by the V108I mutation in the previous study and by the G190A mutation in the present study.
Discussion: Interestingly, we found a high prevalence of G190A, not previously reported in the region; and the absence of V108I, found about equally often as K103N in our previous study during 2003-2005.


  Drug resistance mutations in HIV pol sequences from Argentinean patients under antiretroviral treatment: subtype, gender, and age issues.
 PMID: 21936717       2012       AIDS research and human retroviruses
Abstract: The most common DRMs were L10I, I54V, L90M, V82A, A71V, L10V, M46I, M184V, M41L, T215Y, D67N, L210W, K70R, N348I, V118I, K103N, Y181C, G190A, K101E, V108I, L100I, V90I, K101Q, and  PMID: 22363673       2012       PloS one
Discussion: For example, Yap et al reported that failure of AZT and nevirapine therapy was associated with the emergence of N348I, TAMs, and the non-nucleoside RT inhibitor resistance mutations K103N, V108I, Y181C/I and G190A/S.



Browser Board

 Co-occurred Entities




   Filtrator